{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:23:12Z","timestamp":1785810192834,"version":"3.56.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2]]},"abstract":"\n Background:<\/jats:title>\n Pemetrexed is an antifolate cytostatic drug that targets multiple enzymes involved in folate biosynthesis and is indicated for treatment of non\u2013small-cell lung cancer and malignant pleural mesothelioma. As evidence for an exposure\u2013response\/toxicity relationship is accumulating, dose individualization using therapeutic drug monitoring may be a feasible strategy to optimize treatment. The purpose of this study was to develop a simple, sensitive, high-performance liquid chromatography method with UV detection for quantification of pemetrexed levels in human plasma.<\/jats:p>\n <\/jats:sec>\n \n Method:<\/jats:title>\n The method involves a simple protein precipitation, followed by ultra-performance liquid chromatography with ultraviolet detection at a wavelength of 254 nm. Pemetrexed was separated using a mobile phase with a linear gradient and a run time of only 7 minutes.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n The assay has been validated over the concentration range 0.25\u2013500 mg\/L of pemetrexed. Accuracy for this assay ranged from \u22124.50% to 1.78%, and the within- and between-run coefficients of variation were <3.57%. Pemetrexed in plasma was proven to be stable for 8 months at \u221240\u00b0C.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n The bioanalytical method we developed proved to be simple, accurate, precise, and fast. This analytical method is successfully in use for therapeutic drug monitoring and will be used for pharmacokinetic studies.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000672","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T07:12:35Z","timestamp":1564125155000},"page":"146-150","source":"Crossref","is-referenced-by-count":7,"title":["Simple and Rapid Quantification of the Multi-Enzyme Targeting Antifolate Pemetrexed in Human Plasma"],"prefix":"10.1097","volume":"42","author":[{"given":"Erik","family":"van den Hombergh","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"de Rouw","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen;"},{"name":"ZANOB Hospital Pharmacy, Jeroen Bosch Hospital, 's-Hertogenbosch;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"van den Heuvel","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Croes","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, University Hospital of Maastricht, Maastricht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Derijks","sequence":"additional","affiliation":[{"name":"ZANOB Hospital Pharmacy, Jeroen Bosch Hospital, 's-Hertogenbosch;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nielka P.","family":"van Erp","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2165\/11202640-000000000-00000","article-title":"Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer","volume":"69","author":"Baldwin","year":"2009","journal-title":"Drugs."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/1078-0432.982.11.3","article-title":"Pemetrexed in malignant pleural mesothelioma","volume":"11","author":"Hazarika","year":"2005","journal-title":"Clin Cancer Res."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00280-005-0035-2","article-title":"Clinical application of a semimechanistic-physiologic population PK\/PD model for neutropenia following pemetrexed therapy","volume":"57","author":"Latz","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00280-005-0036-1","article-title":"Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients","volume":"57","author":"Latz","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1681\/ASN.2015050542","article-title":"CKD prevalence varies across the European general population","volume":"27","author":"Bruck","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00408-008-9123-5","article-title":"Lung cancer and renal insufficiency: prevalence and anticancer drug issues","volume":"187","author":"Launay-Vacher","year":"2009","journal-title":"Lung."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.cllc.2015.01.001","article-title":"Estimated creatinine clearance rate is associated with the treatment effectiveness and toxicity of pemetrexed as continuation maintenance therapy for advanced nonsquamous non-small-cell lung cancer","volume":"16","author":"Chen","year":"2015","journal-title":"Clin Lung Cancer."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"S455","DOI":"10.1097\/01.JTO.0000283390.06980.49","article-title":"Correlation of pemetrexed (PEM) NSCLC exposure-response relationships (ERRs) to clinical study results from western and Japanese patient populations","volume":"2","author":"Latz","year":"2007","journal-title":"J Thorac Oncol."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00280-005-0077-5","article-title":"A semimechanistic-physiologic population pharmacokinetic\/pharmacodynamic model for neutropenia following pemetrexed therapy","volume":"57","author":"Latz","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","article-title":"Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function","volume":"24","author":"Mita","year":"2006","journal-title":"J Clin Oncol."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1248\/bpb.b15-00162","article-title":"Risk factors for predicting severe neutropenia induced by pemetrexed plus carboplatin therapy in patients with advanced non-small cell lung cancer","volume":"38","author":"Ikesue","year":"2015","journal-title":"Biol Pharm Bull."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0378-4347(93)E0447-X","article-title":"Column-switching high-performance liquid chromatographic method for the determination of a thymidylate synthase inhibitor, LY231514, an investigational agent for the treatment of solid tumors, in human plasma","volume":"654","author":"Hamilton","year":"1994","journal-title":"J Chromatogr B Biomed Appl."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpba.2016.04.036","article-title":"A new quantification method for assessing plasma concentrations of pemetrexed and its polyglutamate metabolites","volume":"128","author":"Stoop","year":"2016","journal-title":"J Pharm Biomed Anal."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jchromb.2009.06.020","article-title":"Development and validation of an improved liquid chromatography-mass spectrometry method for the determination of pemetrexed in human plasma","volume":"877","author":"Bobin-Dubigeon","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.lungcan.2019.01.018","article-title":"Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis","volume":"130","author":"de Rouw","year":"2019","journal-title":"Lung Cancer."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1535-7163.MCT-06-0343","article-title":"Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications","volume":"6","author":"Chattopadhyay","year":"2007","journal-title":"Mol Cancer Ther."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:32:04Z","timestamp":1692052324000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000672","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}